# Bloomage Gag

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bloomage-gag

- Headquarters: Shenzhen, China
- Website: www.bloomagegag.com/
- Latest round: Series A (Aug 19, 2025)
- Investors on record: 2

## About

Bloomage Biotechnology Co., Ltd., founded in 2023 and headquartered in Shenzhen, China, is engaged in the synthesis of heparin polysaccharides. The company has secured a single funding deal as of August 2025, indicating its proactive engagement in the biotechnology sector. No specific pivots or changes in strategy have been noted during its brief history. In August 2025, Bloomage Gag closed series A funding from new investors SGSD Group and Zhongke Xianjin Fund.

Bloomage Biotechnology Co., Ltd. specializes in the innovative synthesis of heparin polysaccharides and the development of novel pharmaceuticals. Utilizing advanced synthetic biology technologies, the company has created a unique platform for in vitro enzymatic synthesis, addressing key issues related to supply chain security and ethical concerns. Their customer base includes pharmaceutical companies and research institutions across North America, Europe, and parts of Asia.

The revenue model for Bloomage Biotechnology Co., Ltd. is structured around B2B transactions, collaborating with pharmaceutical firms and research entities to supply heparin polysaccharides and related enzyme products. These transactions occur through direct sales agreements or strategic partnerships, where customized pricing is established based on volume and contracts, focusing on proprietary heparin derivatives and enzyme formulations integrated into therapeutic applications.

The revenue model for Bloomage Biotechnology Co., Ltd. is structured around B2B transactions, collaborating with pharmaceutical firms and research entities to supply heparin polysaccharides and related enzyme products. These transactions occur through direct sales agreements or strategic partnerships, where customized pricing is established based on volume and contracts, focusing on proprietary heparin derivatives and enzyme formulations integrated into therapeutic applications.

## Funding rounds

- Series A, Aug 19, 2025 — Zhongke Xianjin Fund, SGSD Group

## Investors

- Zhongke Xianjin Fund (https://capitalatlas.ai/funds/zhongke-xianjin-fund) — Series A
- SGSD Group — Series A